ARMP Stock Summary and Trading Ideas (Armata Pharmaceuticals | AMEX:ARMP)

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Armata Pharmaceuticals trades on the AMEX stock market under the symbol ARMP.

As of April 25, 2024, ARMP stock price climbed to $2.58 with 3,765 million shares trading.

ARMP has a market cap of $93.17 million. This is considered a Micro Cap stock.

Last quarter Armata Pharmaceuticals reported $2 million in Revenue and -$.55 earnings per share. This beat revenue expectation by $668,000 and missed earnings estimates by -$.20.

In the last 3 years, ARMP stock traded as high as $6.49 and as low as $.83.

The top ETF exchange traded funds that ARMP belongs to (by Net Assets): VXF, VTI, IWC.

ARMP has outperformed the market in the last year with a return of +60.2%, while the SPY ETF gained +23.1%. However, in the most recent history, ARMP shares have underperformed the stock market with its stock returning -34.7% in the last 3 month period and -24.1% for the last 2 week period, while SPY has returned +3.6% and -2.5%, respectively.

ARMP support price is $2.29 and resistance is $2.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARMP stock will trade within this expected range on the day.